Co-Authors
This is a "connection" page, showing publications co-authored by CHARLES F LEVENBACK and LOIS M RAMONDETTA.
Connection Strength
0.895
-
Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer. 2004 Jul-Aug; 14(4):580-8.
Score: 0.242
-
Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
Score: 0.125
-
Work related stress among gynecologic oncologists. Gynecol Oncol. 2011 Nov; 123(2):365-9.
Score: 0.099
-
Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol. 2010 Nov; 119(2):291-4.
Score: 0.092
-
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
Score: 0.064
-
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed m?llerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36.
Score: 0.057
-
Mixed choriocarcinoma in a postmenopausal patient. Int J Gynecol Cancer. 2002 May-Jun; 12(3):312-6.
Score: 0.052
-
Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul; 82(1):156-61.
Score: 0.049
-
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
Score: 0.036
-
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9.
Score: 0.023
-
Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
Score: 0.022
-
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
Score: 0.019
-
A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):442-8.
Score: 0.015